Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE. Goetze TO, et al. Among authors: behringer dm. Ann Surg Oncol. 2024 Apr 4. doi: 10.1245/s10434-024-15145-8. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38575722 No abstract available.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE. Goetze TO, et al. Among authors: behringer dm. Ann Surg Oncol. 2024 Mar 8. doi: 10.1245/s10434-024-15011-7. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38459418
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
A scuticociliate causes mass mortality of Diadema antillarum in the Caribbean Sea.
Hewson I, Ritchie IT, Evans JS, Altera A, Behringer D, Bowman E, Brandt M, Budd KA, Camacho RA, Cornwell TO, Countway PD, Croquer A, Delgado GA, DeRito C, Duermit-Moreau E, Francis-Floyd R, Gittens S Jr, Henderson L, Hylkema A, Kellogg CA, Kiryu Y, Kitson-Walters KA, Kramer P, Lang JC, Lessios H, Liddy L, Marancik D, Nimrod S, Patterson JT, Pistor M, Romero IC, Sellares-Blasco R, Sevier MLB, Sharp WC, Souza M, Valdez-Trinidad A, van der Laan M, Vilanova-Cuevas B, Villalpando M, Von Hoene SD, Warham M, Wijers T, Williams SM, Work TM, Yanong RP, Zambrano S, Zimmermann A, Breitbart M. Hewson I, et al. Among authors: behringer d. Sci Adv. 2023 Apr 21;9(16):eadg3200. doi: 10.1126/sciadv.adg3200. Epub 2023 Apr 19. Sci Adv. 2023. PMID: 37075109 Free PMC article.
139 results